GHRS Stock Summary and Trading Ideas (GH Research PLC - | NASDAQ:GHRS)

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

GH Research PLC - trades on the NASDAQ stock market under the symbol GHRS.

As of April 21, 2026, GHRS stock price declined to $20.65 with 438,016 million shares trading.

GHRS has a beta of 1.61, meaning it tends to be more sensitive to market movements. GHRS has a correlation of 0.14 to the broad based SPY ETF.

GHRS has a market cap of $1.28 billion. This is considered a Small Cap stock.

In the last 3 years, GHRS traded as high as $24.66 and as low as $5.05.

The top ETF exchange traded funds that GHRS belongs to (by Net Assets): IBB, PSIL, EIRL, BBC, GWX.

GHRS has outperformed the market in the last year with a price return of +126.9% while the SPY ETF gained +35.2%. GHRS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +31.1% and +36.4%, respectively, while the SPY returned +4.2% and +6.9%, respectively.

GHRS support price is $20.46 and resistance is $22.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GHRS shares will trade within this expected range on the day.